Key Points
- Director James Foster sold 28,733 CRL shares for approximately $7.9 million at an average price of $275, reducing his direct ownership by 47.6%. The transaction occurred under a pre-arranged Rule 10b5-1 trading plan.
- Charles River reported quarterly earnings of $3.02 per share, beating the $2.77 consensus estimate, while revenue of about $1.0 billion also exceeded expectations. Fiscal 2026 earnings guidance remains $11.15–$11.45 per share.
- Investor sentiment remains generally positive: analysts assign the stock a consensus “Moderate Buy” rating, while CRL shares trade near a 52-week high despite additional insider sales by company executives.
Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) Director James Foster sold 28,733 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $275.00, for a total transaction of $7,901,575.00. Following the sale, the director directly owned 31,596 shares in the company, valued at $8,688,900. The trade was a 47.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Charles River Laboratories International Trading Up 1.7%
Shares of NYSE CRL opened at $281.70 on Wednesday. The firm has a 50 day moving average price of $218.88 and a two-hundred day moving average price of $189.84. The stock has a market cap of $13.45 billion, a P/E ratio of -58.08, a price-to-earnings-growth ratio of 2.87 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52-week low of $144.26 and a 52-week high of $282.39. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.25. The company had revenue of $1 billion for the quarter, compared to analysts' expectations of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. Charles River Laboratories International's revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 11.34 EPS for the current year.
More Charles River Laboratories International News
Here are the key news stories impacting Charles River Laboratories International this week:
- Positive Sentiment: Analyst support remains favorable. Piper Sandler set a $300 price target, while Barclays maintained an overweight rating and a $300 target. RBC also raised its target to $282 and reiterated an outperform rating. Overall, 12 analysts rate CRL a Buy, three recommend Hold and one recommends Sell, producing a consensus “Moderate Buy” rating. Charles River Laboratories International Given Consensus Rating of Moderate Buy
- Positive Sentiment: Recent operating results exceeded expectations. Charles River reported quarterly adjusted earnings of $3.02 per share versus the $2.77 consensus estimate, while revenue of approximately $1.0 billion topped expectations of $980.5 million. Fiscal 2026 earnings guidance remains $11.15 to $11.45 per share.
- Positive Sentiment: Strong momentum has attracted attention. CRL reached a new 52-week high near $277, with trading volume above its average. The stock is also well above its 50-day and 200-day moving averages, indicating continued technical momentum. Charles River Laboratories International Sets New 52-Week High
- Neutral Sentiment: International-market exposure remains an investor focus. A recent analysis examines how Charles River’s international revenue trends could affect Wall Street forecasts and the stock’s outlook, but the provided report does not identify a specific estimate change. International Markets and Charles River Deep Dive
- Negative Sentiment: Several insiders sold shares. Director James C. Foster sold 28,733 shares for approximately $7.9 million under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 47.6%. EVP Victoria Creamer sold 4,179 shares worth about $1.1 million, and CAO Michael Gunnar Knell sold 6,645 shares worth approximately $1.7 million. These planned transactions may raise caution, although they do not necessarily signal deteriorating business prospects. SEC insider transaction filing
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in CRL. Jones Financial Companies Lllp increased its holdings in Charles River Laboratories International by 167.6% in the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company's stock worth $253,000 after purchasing an additional 1,074 shares in the last quarter. Empowered Funds LLC acquired a new stake in shares of Charles River Laboratories International during the 1st quarter worth approximately $418,000. American Century Companies Inc. grew its position in shares of Charles River Laboratories International by 41.9% during the 2nd quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company's stock worth $830,000 after buying an additional 1,616 shares during the period. Brown Advisory Inc. increased its stake in shares of Charles River Laboratories International by 5.1% in the 2nd quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company's stock valued at $354,000 after acquiring an additional 114 shares in the last quarter. Finally, California Public Employees Retirement System increased its stake in shares of Charles River Laboratories International by 3.9% in the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company's stock valued at $12,837,000 after acquiring an additional 3,198 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on CRL shares. Weiss Ratings upgraded Charles River Laboratories International from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 1st. JPMorgan Chase & Co. upgraded Charles River Laboratories International from a "neutral" rating to an "overweight" rating and upped their target price for the company from $180.00 to $310.00 in a report on Thursday, August 6th. TD Cowen increased their target price on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the company a "buy" rating in a research report on Monday. Evercore restated an "outperform" rating on shares of Charles River Laboratories International in a report on Wednesday, August 5th. Finally, Mizuho set a $264.00 price target on shares of Charles River Laboratories International in a research report on Monday. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $255.65.
Get Our Latest Stock Analysis on CRL
About Charles River Laboratories International
(
Get Free Report)
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
